Dr Michael Tagen gained an interest in neuropharmacology at a young age. This led him to pursue undergraduate studies in neuroscience and a Ph.D. in pharmacology. He has performed research in several therapeutic areas, including cancer, immunology, and pain. Dr Tagen has spent the past 15 years working in clinical pharmacology and drug development. He has been a scientific advisor for companies developing cannabinoid medicines since 2016. He co-founded Verdient Science, a consulting firm specializing in cannabinoids and psychedelics. Dr. Tagen earned a B.A. in Neuroscience and a Ph.D. in Pharmacology & Experimental Therapeutics.